Latest 10-K annual reports
NASDAQ
BZFD
Buzzfeed, INCBuzzFeed, Inc. reported a significant net loss and cash burn for 2025, raising substantial doubt about its ability to continue as a going concern, while also receiving a Nasdaq delisting notice.
NASDAQ
First Community Corporation announced a significant increase in net income and earnings per share for 2025, driven by robust net interest income and non-interest income growth, alongside strategic acquisition activities.
NASDAQ
GOAI
Eva Live INCEva Live Inc. achieved significant revenue growth and returned to profitability in fiscal year 2025, driven by increased client spending and strategic AI platform enhancements, despite ongoing liquidity concerns and high-cost debt financing.
Cypherpunk Technologies Inc. reports a significant net income for 2025 driven by an unrealized gain on its Zcash holdings, following a strategic pivot to privacy technology while scaling back its biotechnology operations.
NYSE
Summit Midstream Corporation reported a significantly reduced net loss for 2025, driven by strategic acquisitions, debt refinancing, and expanded Permian operations, while resuming preferred stock dividends.
NASDAQ
PLBY
Plby Group, INCPlayboy, Inc. reported a significant reduction in net loss for fiscal year 2025, driven by increased licensing revenue and a strategic shift to a capital-light business model, despite ongoing internal control weaknesses.
NYSE
SmartFinancial, Inc. reported a significant increase in net income and record loan and deposit growth for 2025, alongside strategic capital management and a focus on cybersecurity.
Teads Holding Co. reported a significant net loss of $517.1 million in 2025, driven by a major acquisition, goodwill impairment, and restructuring charges, despite substantial revenue growth.
OTC.Pink
Franklin BSP Capital Corporation's 2025 annual report highlights increased investment income and a diversified portfolio, alongside net realized and unrealized losses and ongoing market uncertainties.
NYSE
Greystone Housing Impact Investors LP reported a net loss of $7.6 million in 2025 and identified a material weakness in its internal controls over financial reporting.
NASDAQ
Capital Bancorp, Inc. announced an 84.6% surge in net income to $57.2 million for 2025, driven by the IFH acquisition and organic growth, despite rising nonperforming assets and an internal control weakness.
NASDAQ
ATN International, Inc. reported a significantly narrowed net loss in 2025, driven by reduced operating expenses and strategic shifts in its US Telecom segment, alongside ongoing network modernization and a planned tower portfolio sale.
NYSE
HLLY
Holley INCHolley Inc. reported a significant turnaround in 2025, achieving net income and substantial gross margin improvement, driven by operational efficiencies and higher pricing.
NYSE
Flotek Industries, Inc. reported a significant increase in total revenues and net income for the fiscal year ended December 31, 2025, driven by growth in both Chemistry Technologies and Data Analytics segments.
AMEX
OGEN
Oragenics INCOragenics, Inc. reports continued operating losses and a going concern doubt, while advancing its lead mild traumatic brain injury drug candidate, ONP-002, into Phase 2a clinical trials in Q1 2026.
NASDAQ
Siddhi Acquisition Corp, a SPAC, reported a net loss of $223,387 for the year ended December 31, 2025, as it continues its search for a business combination target.
NASDAQ
HF Foods Group Inc. reported a net loss of $38.8 million for 2025, an improvement from the prior year, alongside a full goodwill impairment and strategic operational expansions.
NYSE
Douglas Elliman Inc. reported a significant turnaround in 2025, achieving net income and positive operating income, driven by the strategic sale of its property management business and increased average transaction values.
NASDAQ
RPD
Rapid7, INCRapid7, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for fiscal year 2025 to include an inadvertently omitted Compensation Recoupment Policy.
First Foundation Inc. reported a net loss of $155.2 million for 2025, alongside a pending merger with FirstSun Capital Bancorp and identified material weaknesses in internal controls.
NASDAQ
Silvercrest Asset Management Group Inc. reported a 1.3% revenue increase to $125.3 million in 2025, but net income declined significantly by 48.7% to $8.06 million, driven by increased expenses and net client outflows.
OID
Ludwig Enterprises, an early-stage genomic diagnostics company, reported significant losses and a going concern warning in its 2025 annual report, despite advancing its Revealia Breast test towards a Q2 2026 trial launch.
OID
CSBB
Csb Bancorp, INCCSB Bancorp, Inc. announced a 33.5% increase in net income to $13.4 million for 2025, driven by higher net interest income and improved credit loss expense.
NASDAQ
Universal Logistics Holdings, Inc. reported a substantial net loss and operating loss for 2025, driven by impairment charges and a material weakness in financial reporting.
NYSE
Once Upon a Farm, PBC announced a 53% increase in net sales for 2025, reaching $240.7 million, driven by product innovation and expanded distribution, while narrowing its net loss and completing a significant IPO.
NYSE
Ardent Health, Inc. reported a 6.0% revenue increase in 2025 but saw net income decline significantly due to surging professional liability costs and the impact of new federal healthcare legislation.
AMEX
Perspective Therapeutics, a radiopharmaceutical developer, reported significant R&D investment and clinical progress for its alpha-particle therapies, alongside a recent $175 million capital raise, despite continued net losses.
NYSE
Dell Technologies reported a 19% increase in net revenue for Fiscal 2026, reaching $113.5 billion, primarily fueled by significant demand for AI-optimized servers and disciplined cost management.
NYSE
IOT
Samsara INCSamsara Inc. reported a significant reduction in net loss and robust revenue growth for fiscal year 2026, driven by increased customer adoption and expanded platform usage.
FGEN
Fibrogen INCKyntra Bio, formerly FibroGen, completed the sale of its China operations for $220.4 million, significantly improving liquidity while advancing its oncology and myelodysplastic syndromes pipeline.